ArticleLiver international : official journal of the International Association for the Study of the Liver2025
Feasibility and Safety of Cytosorb Application in Patients With Acute Liver Failure.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Feasibility and Safety of Cytosorb Application in Patients With Acute Liver Failure.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsAcute liver failure (ALF) is a rare, life-threatening condition with high mortality and limited therapeutic options beyond liver transplantation. Cytosorb adsorber can be easily applied to continuous renal replacement therapy (CRRT) and potentially support liver function by removing bilirubin and cytokines.
methodsThis retrospective single-centre study included all ALF patients admitted to the intensive care unit (ICU) at the Division of Gastroenterology and Hepatology of the Vienna General Hospital from 2012 to 2025 receiving CRRT.
resultsTwenty-eight ALF patients (median SOFA 11, SAPS II 43) were included, with high incidences of vasopressor use (82.1%) and invasive ventilation (85.7%). Fourteen received adjunctive Cytosorb therapy. Complications (hemodynamic instability, citrate accumulation, bleeding, hypofibrinogenemia, thrombocytopenia) were similar in patients with or without Cytosorb. Bilirubin levels significantly decreased after Cytosorb initiation (from 20.85 to 12.32 mg/dL at 24 h, and to 9.46 mg/dL after treatment; p < 0.001), GGT, ALAT, and platelets also declined post-treatment. Cytosorb patients had lower SAPS II scores (median: 38.5 vs. 45.5, p = 0.039), were more often listed for HU-LTx (92.9% vs. 42.9%, p = 0.005), and had higher transplantation rates (64.3% vs. 28.6%, p = 0.058). Therefore, ICU survival (71.4% vs. 42.9%; p = 0.127) and 6-month survival (71.4% vs. 28.6%; p = 0.023) were higher in the Cytosorb group.
conclusionsCytosorb appeared to be a feasible and well-tolerated blood purification tool with potential beneficial effects in ALF patients. Improved survival with Cytosorb likely reflects confounding by patient selection and higher HU-LTx rates. Prospective studies are warranted to clarify the clinical impact of adjunctive Cytosorb therapy in ALF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.